title: Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study.
abstract: Twenty patients with stage IIIA-IIIB non-small-cell lung cancer were treated with cisplatin, epirubicin and VP-16 (PEV) neoadjuvant chemotherapy (CDDP, 70 mg/m2, i.v., d 1; EDX, 60 mg/m2, i.v., d 1; VP-16, 100 mg/m2, i.v., d 1-2-3; every 3 weeks). A partial response was obtained in 11 cases (55%), stable disease in 3 cases (15%), and progressive disease in 6 cases (30%). After chemotherapy, 8 (40%) patients, all achieving a partial response, were elegible for surgery: 5 (25%) had a complete resection (4 IIIA and 1 IIIB) and 3 (15%) an incomplete resection. The treatment was well tolerated. These data show that PEV is an active regimen for neoadjuvant chemotherapy in NSCLC and recommend this therapeutic approach for stage IIIA patients.
authors.affiliation: Cattedra di Oncologia Medica, II Facoltà di Medicina, Università di Napoli, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Gridelli
authors.forename: S
authors.initials: S
authors.lastname: Iacobelli
authors.forename: T
authors.initials: T
authors.lastname: Martino
authors.forename: C
authors.initials: C
authors.lastname: Natoli
authors.forename: G
authors.initials: G
authors.lastname: Ferrante
authors.forename: M
authors.initials: M
authors.lastname: Gentile
authors.forename: L
authors.initials: L
authors.lastname: Irtelli
authors.forename: V
authors.initials: V
authors.lastname: Beltrami
authors.forename: A
authors.initials: A
authors.lastname: Rossi
authors.forename: A R
authors.initials: AR
authors.lastname: Bianco
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010865:Pilot Projects; D016896:Treatment Outcome
chemical_list: D015251:Epirubicin; D005047:Etoposide; D002945:Cisplatin